Call for Abstracts

Note

All presentations in the APGCC × JGCA Joint Session are by invitation only, and abstract submissions are not open to the public.
Abstracts from overseas presenters will be accepted collectively through our co-hosted congress, JGCA2026.
Submitted abstracts will be officially recognized as part of the programs of both APGCC2026 and JGCA2026, and will be counted toward the official participation record of both congresses.

Abstract Submission Period

Abstracts for oral, poster

Wednesday, 9 July, 12:00 PM (JST) – Wednesday, 27 August, 12:00 PM (JST)

Abstract Submission

You may revise or delete your submitted abstract as many times as necessary before the submission deadline.
Please note that no changes can be made after the deadline.

To change or update your registration information, please click the “Confirmation / Modification” button.

Abstract Submission

Confirmation / Modification

This system is confirmed to work with Google Chrome, Microsoft Edge, and Safari.
Please do not use any other browser.

Safari is supported on version 2.0.3 (417.9.2) or later. Older versions are not compatible.

Presentation Style/Categories

Please select the most appropriate category for your presentation.

Main session style

Oral presentation

Main session category

Symposium

Frontline of New Drug Development – Expectations for Gastric Cancer

Detail

The global landscape of pharmaceutical development is undergoing significant transformation. In addition to traditional small molecule drugs and antibody therapeutics, a wide variety of new modalities – including antibody-drug conjugates, T cell engagers, CAR-T therapies (regenerative medicine), and medium-sized molecule drugs – are being developed for various cancer types.
This session will discuss the latest trends and future prospects of drugs and seeds that are currently under development or may be developed for gastric cancer.

Cutting-Edge Robotic Surgery: The Next Frontier

Detail

Robotic surgery has rapidly evolved from experimental systems to mainstream surgical platforms, especially in gastrointestinal oncology. This session will explore the latest technological advancements, clinical outcomes, and future directions of robotic-assisted procedures. By gathering leading experts, we aim to discuss current challenges, integration into standard care, and how robotic innovation continues to redefine surgical precision and patient safety.

Panel discussion

Present and future perspective of AI/Digital Pathology

Detail

Driven by the recent progress of digital technologies and artificial intelligence, pathology is undergoing a period of significant advancement. With the convergence of digital pathology, image recognition programs empowered by machine/deep learning, and bioinformatics developed through genomic medicine, we are beginning to envision a new future. We would like to deepen our discussion by inviting pathologists and researchers with expertise in this field to share the latest insights.

Surgical Strategies in Reconstruction After Proximal Gastrectomy: Balancing Function and Safety

Detail

Proximal gastrectomy (PG) has gained renewed attention as a function-preserving surgical option for upper-third gastric cancer. However, the choice of reconstruction method remains controversial due to the need to balance postoperative function, complication risks, and long-term quality of life. This session will focus on the current strategies for reconstruction after PG, including techniques such as esophagogastrostomy, double tract reconstruction, and jejunal interposition. Experts will present recent data, technical tips, and comparative outcomes to identify the most appropriate approach for various clinical situations. Through interactive discussion, we aim to clarify the decision-making process and promote consensus on optimizing both functional outcomes and surgical safety.

Workshop

Impact of AI on managing gastric cancer in endoscopy, pathology, and surgery

Detail

Artificial intelligence (AI)-based devices and technologies are being gradually introduced into clinical practice across various medical fields. Several AI-assisted tools designed to aid in the management of gastric cancer have already been commercialized. In this session, we invite presentations on novel approaches and the development of AI in various areas, such as endoscopy, pathology, and surgery, as well as effective utilization strategies for existing AI-based devices in managing gastric cancer.

General Presentation style

Oral presentation, Poster presentation (Paper style)
If you are submitting a general abstract, we actively encourage Oral presentations and would be grateful if you would consider submitting one.

General Presentation category

1	Epidemiology
2	Molecular biology
3	Pathology
4	Genomics
5	Translational research
6	Biomarker
7	Tumor microenvironment
8	AI
9	Endoscopic therapy
10	Endoscopic diagnosis
11	Imaging diagnosis
12	H. pylori
13	Progression of gastric cancer
14	Rare metastasis / Micrometastasis
15	Intraoperative frozen section
16	Cancer stem cell
17	Clinical pathology
18	Prognostic factor
19	Precision medicine
20	Clinical study
21	Chemotherapy
22	Neoadjuvant chemotherapy
23	Adjuvant chemotherapy
24	Second-line chemotherapy
25	Third-line chemotherapy
26	Intraperitoneal chemotherapy
27	Molecular targeted therapy
28	Immunotherapy
29	Radiation therapy
30	conversion surgery
31	Surgery
32	Laparoscopic surgery
33	Robot surgery
34	Function-preserving surgery
35	Cytoreductive surgery
36	LECS
37	Surgical navigation
38	Postoperative functional assessment
39	Postgastrectomy syndrome
40	Perioperative management
41	Postoperative complications
42	ERAS

43	Navigation Surgery
44	Peritoneal dissemination
45	CART
46	Stent placement
47	Liver metastasis
48	Recurrence
49	Early gastric cancer
50	Advanced gastric cancer
51	Scirrhous gastric cancer
52	Gastric stump carcinoma
53	Multiple gastric cancers
54	Gastric tube cancer
55	Esophago-gastric junction cancer
56	Gastric cancer in elderly patients
57	AFP-producing gastric cancer
58	EBV-related gastric cancer
59	Gastrointestinal stromal tumor
60	Malignant lymphoma
61	Gastric neuroendocrine tumor
62	Guidelines
63	Clinical pathway
64	Postoperative surveillance
65	Long-term survival case after chemotherapy
66	NST
67	Outcome
68	QOL assessment
69	Cachexia
70	Nutrition
71	Obesity
72	Case report
73	Japanese Classification of Gastric Carcinoma
74	Multidisciplinary treatment
75	Palliative therapy
76	Team approach
77	Patient Adovocacy
78	MDT conference
79	Medical cooperation
80	Oral care
81	EFTR
82	Oligometastasis
83	Others

About the Best Poster Session

About the Poster Session for the Best Presentation The best poster abstracts will be selected from among the general abstract (poster) submissions at after a rigorous review process.

Abstract Acceptance or Rejection

Please note that the acceptance or rejection of abstracts, as well as the presentation format, is at the sole discretion of the Congress President.

Travel Grant

The Travel Grant will be awarded to abstracts recognized as outstanding.
The selection process is entirely entrusted to the discretion of the Congress President.

Abstract Submission

Language for abstract

English

Language for presentation

English

Language for presentation slides

English

The number of characters

Title: Up to 120 characters including spaces (approximately 20-24 words)
Abstract: Up to 2,000 characters including spaces (approximately 330-400 words)

* Please note that the abstract will be published as submitted. We kindly ask you to carefully check for any typographical or grammatical errors before submission.

Conflict of Interest Disclosure

The author is required to report applicable COI (Conflict of Interest) by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process.

If there is no COI to disclose

If there is any COI to disclose

Abstract Submission

You may revise or delete your submitted abstract as many times as necessary before the submission deadline.
Please note that no changes can be made after the deadline.

To change or update your registration information, please click the “Confirmation / Modification” button.

Abstract Submission

Confirmation / Modification

This system is confirmed to work with Google Chrome, Microsoft Edge, and Safari.
Please do not use any other browser.

Safari is supported on version 2.0.3 (417.9.2) or later. Older versions are not compatible.

Inquiries

Secretariat of the 98th Annual Meeting of the Japanese Gastric Cancer Association
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-98jgca[A]convention[D]co[D]jp( Please change [A] to @ and [D] to . )